Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis spaced follow-up study in diabetic macular edema
2013-002850-54Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Primary endpoint: Stable best-corrected visual acuity at 24 months versus month 6. Started Sep 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2013-002850-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002850-54.